ホーム › 急性骨髄性白血病 › ミシガン州 › Detroit
Detroit、MIにおける急性骨髄性白血病の臨床試験
Detroitとその周辺地域（約30マイル以内）の拠点で、急性骨髄性白血病に関する14件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
被験者募集中第2相
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
被験者募集中第3相
- Henry Ford Health System, Detroit
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Henry Ford Hospital, Detroit
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Wayne State University/Karmanos Cancer Institute, Detroit
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
被験者募集中第1/2相
- Children's Hospital of Michigan, Detroit
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
被験者募集中第3相
- Children's Hospital of Michigan, Detroit
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
被験者募集中第3相
- Wayne State University School of Medicine, Detroit
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
被験者募集中第1相
- Karmanos Cancer Institute, Detroit
- Henry Ford Cancer Institute, Detroit
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
被験者募集中第3相
- Henry Ford Cancer Institute, Detroit
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- Children's Hospital of Michigan, Detroit
- Henry Ford Health System, Detroit
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
被験者募集中第2相
- Karmanos Cancer Institute, Detroit
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
被験者募集中第1相
- Karmanos Cancer Institute, Detroit
HPC Offered for PRESERVE Expansion
被験者募集中観察研究
- Henry Ford Health, Detroit
他の都市における急性骨髄性白血病の試験
- Houston, TX85件の研究
- New York City, NY51件の研究
- Boston, MA44件の研究
- Seattle, WA41件の研究
- Baldwin Park, CA40件の研究
- Columbus, OH35件の研究
- Philadelphia, PA34件の研究
- Durham, NC33件の研究
- Atlanta, GA31件の研究
- Tampa, FL29件の研究
- Chicago, IL26件の研究
- Portland, OR25件の研究
Detroitにおける他の研究
- 非小細胞肺癌44件の研究
- 乳がん33件の研究
- がん（全種類）29件の研究
- 大腸癌26件の研究
- 卵巣がん26件の研究
- 転移性癌24件の研究
- 前立腺がん22件の研究
- 子宮内膜がん21件の研究
- 肺がん20件の研究
- 多発性骨髄腫19件の研究
- 胃癌16件の研究
- 頭頸部扁平上皮癌15件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。